哌拉西林／他唑巴坦（邦达）治疗细菌性感染疗效观察

目的 :观察邦达治疗细菌性感染的临床疗效及安全性。方法 :以中、重度细菌性感染患者为试验对象 ,参照哌拉西林 (对照A组 ) ,特治星 (进口哌拉西林 他唑巴坦 ) (对照B组 )。将符合病例选择标准的 10 7例患者随机地分入试验组 ( 36例 ) ,对照A组( 36例 ) ,对照B组 ( 35例 ) ,并对其进行治疗、观察。结果 :各组临床有效率分别为 88 9%、6 3 9%和 91 4 % ,各种致病菌感染的临床有效率分别为 92 3%、5 7 6 % ,和 94 3% ;纸片法药敏试验高敏感率分别为 92 3%、6 2 6 %和 94 5 % ;细菌阴转率分别为 92 3% ,6 3 6 %和 94 3% ;细菌清除率分别为 87 2 %、5 4 5 %和 91 4 %。经统计学处理 ,试验组与对照A组各对应的参数间比较均有显著性差异 (P <0 0 2 5 ) ,与对照B组比较各对应的参数间均无显著性差异 (P >0 0 5 )。不良反应发生率分别为 5 5 6 %、8 33%和5 71% ,均无统计学显著性差异 (P >0 0 5 )。结论 :邦达的抗菌疗效明显优于哌拉西林 ;与同类进口药近似 ,临床疗效肯定而无差异但价格便宜 ;且不良反应少 ,安全性高 ,耐受性好 ,对于临床上常见的中、重度细菌性感染 ,尤其是产酶菌引起的感染 ,具有较高的临床应用价值和较好的应用前景

Observation of Clinical Efficacy of Piperacillin/tazobactam in Patients with the Bacterial Infections

OBJECTIVE:To observe the clinical efficacy and safety of Piperacillin/tazobactam(P/T) in the treatment of bacterial infections. METHODS:107 patients with moderate or severe bacterial infections were enrolled in a randomized controlled clinical trial, 36 in trial group, 36 in control group A and 35 in control group B, then treated and observed. RESULTS:The overall clinical efficacy rates (OCER) of P/T, Piperacillin(P),and Tazocin were 88.9%, 63.9% and 91.4% respectively. The OCER of all kinds of bacterial infections were 92.3%, 57.6% and 94.3% respectively. The drug susceptibility rates of the bacteria isolated to P/T, P and Tazocin were 92.3%, 62.6% and 94.5% respectively, and after treatment the negative rates of bacterial were 92.3%, 63.6% and 94.3% respectively, the bacterium eradication rates were 87.2%, 54.5% and 91.4%, there were significant difference between all observed parameters of trial group and control group A ( P <0.025), but the difference between trial group and control group B were no significance ( P >0.025). The adverse drug reaction of the three groups were 5.56%, 8.33% and 5.71% respectively, no significant difference was observed in between trial group and control group A or control group B. CONCLUSION:P/T is of a extensive spectrum, high efficacy and safety in the treatment of moderate to severe bacterial infections.